• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
EMBM - a new enzyme mechanism-based method for rational design of chemical sites of covalent inhibitors.EMBM-一种基于酶机制的新方法,用于合理设计共价抑制剂的化学位点。
J Chem Inf Model. 2010 Dec 27;50(12):2256-65. doi: 10.1021/ci100330y. Epub 2010 Nov 19.
2
A new method for filtering of reactive "warheads" of transition-state analog protease inhibitors.一种用于筛选过渡态类似物蛋白酶抑制剂反应性“弹头”的新方法。
Eur J Med Chem. 2014 Apr 22;77:134-8. doi: 10.1016/j.ejmech.2014.02.059. Epub 2014 Feb 28.
3
Application of EMBM to Structure-Based Design of Warheads for Protease Inhibitors.
Mol Inform. 2014 Jan;33(1):36-42. doi: 10.1002/minf.201300099. Epub 2013 Oct 24.
4
Protocol for rational design of covalently interacting inhibitors.共价相互作用抑制剂的合理设计方案。
Chemphyschem. 2014 Oct 20;15(15):3226-35. doi: 10.1002/cphc.201402542. Epub 2014 Sep 24.
5
Enzyme isoselective inhibitors: application to drug design.
ChemMedChem. 2006 Jun;1(6):639-43. doi: 10.1002/cmdc.200600030.
6
Differentiating serine and cysteine protease mechanisms by new covalent QSAR descriptors.利用新型共价定量构效关系描述符区分丝氨酸蛋白酶和半胱氨酸蛋白酶的作用机制。
Chembiochem. 2011 May 2;12(7):1023-6. doi: 10.1002/cbic.201000459. Epub 2011 Mar 24.
7
Quantitative structure-activity relationship studies of mushroom tyrosinase inhibitors.蘑菇酪氨酸酶抑制剂的定量构效关系研究
J Comput Aided Mol Des. 2008 May;22(5):299-309. doi: 10.1007/s10822-008-9187-6. Epub 2008 Feb 7.
8
Selection of Promising Novel Fragment Sized SrtA Noncovalent Inhibitors Based on QSAR and Docking Modeling Studies.基于 QSAR 和对接建模研究筛选有前途的新型 SrtA 非共价小分子抑制剂。
Molecules. 2021 Dec 19;26(24):7677. doi: 10.3390/molecules26247677.
9
Factors determining the relative stability of anionic tetrahedral complexes in serine protease catalysis and inhibition.
Proteins. 2000 Jul 1;40(1):154-67. doi: 10.1002/(sici)1097-0134(20000701)40:1<154::aid-prot170>3.0.co;2-v.
10
Structure-based QSAR, molecule design and bioassays of protease-activated receptor 1 inhibitors.基于结构的定量构效关系、蛋白酶激活受体 1 抑制剂的分子设计和生物测定。
J Biomol Struct Dyn. 2017 Oct;35(13):2853-2867. doi: 10.1080/07391102.2016.1234413. Epub 2016 Nov 3.

引用本文的文献

1
Structure-based rational design of covalent probes.基于结构的共价探针合理设计。
Commun Chem. 2025 Aug 12;8(1):242. doi: 10.1038/s42004-025-01606-y.
2
From sequence to enzyme mechanism using multi-label machine learning.从序列到多标签机器学习的酶机制。
BMC Bioinformatics. 2014 May 19;15:150. doi: 10.1186/1471-2105-15-150.

本文引用的文献

1
Differentiating serine and cysteine protease mechanisms by new covalent QSAR descriptors.利用新型共价定量构效关系描述符区分丝氨酸蛋白酶和半胱氨酸蛋白酶的作用机制。
Chembiochem. 2011 May 2;12(7):1023-6. doi: 10.1002/cbic.201000459. Epub 2011 Mar 24.
2
The influence of lead discovery strategies on the properties of drug candidates.先导化合物发现策略对候选药物性质的影响。
Nat Rev Drug Discov. 2009 Mar;8(3):203-12. doi: 10.1038/nrd2796.
3
Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.脂肪酸酰胺水解酶(FAAH)抑制剂的发现与开发。
J Med Chem. 2008 Dec 11;51(23):7327-43. doi: 10.1021/jm800311k.
4
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.以α-酮杂环作为关键功能基团的蛋白酶和酰胺水解酶抑制剂。
Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. doi: 10.1016/j.bmc.2007.11.015. Epub 2007 Nov 6.
5
Screening of the active site from water by the incoming ligand triggers catalysis and inhibition in serine proteases.进入的配体将水分子从活性位点排挤出去,从而触发丝氨酸蛋白酶的催化作用和抑制作用。
Proteins. 2008 Mar;70(4):1578-87. doi: 10.1002/prot.21727.
6
Optimization of parameters for semiempirical methods V: modification of NDDO approximations and application to 70 elements.半经验方法参数的优化V:NDDO近似的修正及对70种元素的应用
J Mol Model. 2007 Dec;13(12):1173-213. doi: 10.1007/s00894-007-0233-4. Epub 2007 Sep 9.
7
Development of quantitative structure-activity relationships and its application in rational drug design.定量构效关系的发展及其在合理药物设计中的应用。
Curr Pharm Des. 2006;12(35):4601-11. doi: 10.2174/138161206779010431.
8
Electrostatic basis for enzyme catalysis.酶催化的静电基础。
Chem Rev. 2006 Aug;106(8):3210-35. doi: 10.1021/cr0503106.
9
Enzyme isoselective inhibitors: application to drug design.
ChemMedChem. 2006 Jun;1(6):639-43. doi: 10.1002/cmdc.200600030.
10
Enzyme isoselective inhibitors: a tool for binding-trend analysis.
ChemMedChem. 2006 Jun;1(6):631-8. doi: 10.1002/cmdc.200600029.

EMBM-一种基于酶机制的新方法,用于合理设计共价抑制剂的化学位点。

EMBM - a new enzyme mechanism-based method for rational design of chemical sites of covalent inhibitors.

机构信息

The Julius Spokojny Bioorganic Chemistry Laboratory, Department of Chemistry, Bar Ilan University, Ramat Gan 52900, Israel.

出版信息

J Chem Inf Model. 2010 Dec 27;50(12):2256-65. doi: 10.1021/ci100330y. Epub 2010 Nov 19.

DOI:10.1021/ci100330y
PMID:21090595
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3010454/
Abstract

We introduce an enzyme mechanism-based method (EMBM) aimed at rational design of chemical sites (CS) of reaction coordinate analog inhibitors. The energy of valence reorganization of CS, caused by the formation of the enzyme-inhibitor covalent complex, is accounted for by new covalent descriptors W1 and W2. We considered CS fragments with a carbonyl reactivity center, like in native protease substrates. The W1 and W2 descriptors are calculated quantum mechanically on small molecular clusters simulating the reaction core of the formed covalent tetrahedral complex, anionic TC(O-) or neutral TC(OH). The modeling on a reaction core allows generation of various CS and corresponding TC(O-) and TC(OH) as universal building blocks of real inhibitors and their covalent complexes with serine or cysteine hydrolases. Moreover, the approach avoids the need for 3D structure of the target enzyme, so EMBM may be used for ligand-based design. We have built a chemical site of inhibitors (CSI) databank with pairs of W1 and W2 descriptors precalculated for both CH₃O(-) and CH₃S(-) nucleophiles for every collected CS fragment. We demonstrated that contribution of a CS fragment to the binding affinity of an inhibitor depends on both its covalent reorganization during the chemical transformation and its noncovalent interactions in the enzyme active site. Consequently, prediction of inhibitors binding trend can be done only by accounting for all of these factors, using W1 and W2 in combination with noncovalent QSAR descriptors.

摘要

我们介绍了一种基于酶机制的方法(EMBM),旨在合理设计反应坐标类似物抑制剂的化学位点(CS)。CS 的价重组能,由酶-抑制剂共价复合物的形成引起,由新的共价描述符 W1 和 W2 来解释。我们考虑了具有羰基反应性中心的 CS 片段,就像天然蛋白酶底物一样。W1 和 W2 描述符是在模拟形成的共价四面体复合物、阴离子 TC(O-) 或中性 TC(OH)的反应核心的小分子团簇上进行量子力学计算的。在反应核心上进行建模允许生成各种 CS 以及相应的 TC(O-)和 TC(OH),它们是真实抑制剂及其与丝氨酸或半胱氨酸水解酶形成的共价复合物的通用构建块。此外,该方法避免了对靶酶 3D 结构的需求,因此 EMBM 可用于基于配体的设计。我们构建了一个抑制剂化学位点(CSI)数据库,其中为每个收集的 CS 片段预先计算了 CH₃O(-)和 CH₃S(-)亲核试剂的 W1 和 W2 描述符对。我们证明,CS 片段对抑制剂结合亲和力的贡献取决于其在化学转化过程中的共价重排以及其在酶活性位点中的非共价相互作用。因此,只有通过考虑所有这些因素,使用 W1 和 W2 与非共价 QSAR 描述符相结合,才能预测抑制剂的结合趋势。